Cargando…

Attainment of cholesterol target values in Greece: results from the Dyslipidemia International Study II

INTRODUCTION: Current European guidelines recommend treatment with lipid-lowering therapy (LLT) to a low-density lipoprotein cholesterol (LDL-C) target of < 70 mg/dl for patients at very high risk. LDL-C target attainment and use of LLTs in these patients in Greece is not known. MATERIAL AND METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liberopoulos, Evangelos, Rallidis, Loukianos, Spanoudi, Filio, Xixi, Elena, Gitt, Anselm, Horack, Martin, Ashton, Veronica, Brudi, Philippe, Lautsch, Dominik, Ambegaonkar, Baishali, Elisaf, Moses
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2018
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657251/ https://www.ncbi.nlm.nih.gov/pubmed/31360176 http://dx.doi.org/10.5114/aoms.2018.73961

Ejemplares similares

Do acute coronary events affect lipid management and cholesterol goal attainment in Germany?: Results from the Dyslipidemia International study II
por: Gitt, Anselm K., et al.
Publicado: (2018)

Body mass index impacts the choice of lipid‐lowering treatment with no correlation to blood cholesterol – Findings from 52 916 patients in the Dyslipidemia International Study (DYSIS)
por: Ferrières, Jean, et al.
Publicado: (2018)

Prevalence of lipid abnormalities and cholesterol target value attainment in Egyptian patients presenting with an acute coronary syndrome
por: Sobhy, Mohamed, et al.
Publicado: (2018)

Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885 statin-treated patients by country and region across the world
por: Gitt, Anselm K., et al.
Publicado: (2016)

Prevalence of Lipid Abnormalities and Cholesterol Target Value Attainment in Patients with Stable and Acute Coronary Heart Disease in the United Arab Emirates
por: Al Mahmeed, Wael, et al.
Publicado: (2019)

Dyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in Korea
por: Lee, Sang-Hak, et al.
Publicado: (2019)

Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia
por: Al Sifri, Saud, et al.
Publicado: (2018)

Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world
por: Gitt, Anselm K., et al.
Publicado: (2018)

Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world
por: Gitt, Anselm K., et al.
Publicado: (2017)

Attainment of multifactorial treatment targets among the elderly in a lipid clinic
por: Barkas, Fotios, et al.
Publicado: (2015)

How does the TRS 2°P score relate to real-world patients?
por: Bonaca, Marc P, et al.
Publicado: (2018)

Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study
por: Azar, Sami T, et al.
Publicado: (2014)

Contemporary Management and Attainment of Cholesterol Targets for Patients with Dyslipidemia in China
por: Gao, Fei, et al.
Publicado: (2013)

Editorial: Secondary Dyslipidemias
por: Elisaf, Moses, et al.
Publicado: (2011)

Life-threatening hypophosphataemia in a cirrhotic patient with jaundice
por: Moutzouri, Elisavet, et al.
Publicado: (2011)

Assessing forgetfulness and polypharmacy and their impact on health-related quality of life among patients with hypertension and dyslipidemia in Greece during the COVID-19 pandemic
por: Souliotis, Kyriakos, et al.
Publicado: (2021)

Electrolyte and acid-base disorders in inflammatory bowel disease
por: Barkas, Fotis, et al.
Publicado: (2013)

No effect of fenugreek, bergamot and olive leaf extract on glucose homeostasis in patients with prediabetes: a randomized double-blind placebo-controlled study
por: Florentin, Matilda, et al.
Publicado: (2019)

Results of the Dyslipidemia International Study (DYSIS)-Middle East: Clinical Perspective on the Prevalence and Characteristics of Lipid Abnormalities in the Setting of Chronic Statin Treatment
por: Al Sifri, Saud N., et al.
Publicado: (2014)

Dyslipidemia Associated with Chronic Kidney Disease
por: Tsimihodimos, Vasilis, et al.
Publicado: (2011)

Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study
por: Kei, Anastazia, et al.
Publicado: (2011)

Management of the COVID-19 pandemic in Rhineland-Palatinate hospitals of all levels of care: Results of the COVID-19 Registry RLP
por: Gitt, Anselm K., et al.
Publicado: (2023)

Mixed dyslipidemias in primary care patients in France
por: Laforest, Laurent, et al.
Publicado: (2012)

Treatment patterns and risk factor control in patients with and without metabolic syndrome in cardiac rehabilitation
por: Gitt, Anselm, et al.
Publicado: (2012)

No effect of vitamin D supplementation on cardiovascular risk factors in subjects with metabolic syndrome: a pilot randomised study
por: Makariou, Stefania E., et al.
Publicado: (2017)

Statin escape phenomenon: Fact or fiction?
por: Barkas, Fotios, et al.
Publicado: (2017)

Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia
por: Kei, Anastazia, et al.
Publicado: (2014)

Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?
por: Filippatos, Theodosios D., et al.
Publicado: (2017)

Adherence to Statin Therapy and Attainment of LDL Cholesterol Goal Among Patients with Type 2 Diabetes and Dyslipidemia
por: Alwhaibi, Monira, et al.
Publicado: (2019)

The relationship of vitamin D with non-traditional risk factors for cardiovascular disease in subjects with metabolic syndrome
por: Makariou, Stefania, et al.
Publicado: (2012)

The effect of combining rosuvastatin with sartans of different peroxisome proliferator receptor-γ activating capacity on plasma 8-isoprostane prostaglandin F(2a) levels
por: Rizos, Christos V., et al.
Publicado: (2013)

Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA)
por: Pettersson, Billie, et al.
Publicado: (2010)

Effects of increased body weight and short-term weight loss on serum PCSK9 levels – a prospective pilot study
por: Filippatos, Theodosios D, et al.
Publicado: (2017)

Vitamin D status and cardiometabolic risk factors in Greek adolescents with obesity – the effect of vitamin D supplementation: a pilot study
por: Makariou, Stefania E., et al.
Publicado: (2020)

Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry
por: Rizos, Christos V., et al.
Publicado: (2020)

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
por: Moutzouri, Elisavet, et al.
Publicado: (2010)

ST-elevation myocardial infarction in a 39-year-old patient with “normal” coronary arteries as a thrombotic complication of COVID-19
por: Liori, Sotiria, et al.
Publicado: (2021)

Lipoprotein(a): Its Association with Calcific Aortic Valve Stenosis, the Emerging RNA-Related Treatments and the Hope for a New Era in “Treating” Aortic Valve Calcification
por: Tsamoulis, Donatos, et al.
Publicado: (2023)

An ominous triad: acute inferior ST-segment elevation myocardial infarction, right ventricular infarction, and ventricular septal rupture/dissection
por: Rallidis, Loukianos S, et al.
Publicado: (2023)

Effects of Eprosartan on Serum Metabolic Parameters in Patients with Essential Hypertension
por: Rizos, Evangelos C, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_6lpvjjd1bvqba5fklk5oa2oo16